$TILE

Interface, Inc. Q2 2026 Earnings Call Summary

Interface, Inc. reported 4% currency-neutral Q2 2026 net sales growth on its One Interface strategy. Healthcare delivered 19% global billings growth. The company raised full-year 2026 guidance, citing 22% backlog growth and expects ~39% second-half gross margin run rate. Q2 included a $15.6M IEEPA tariff refund benefit (~$0.19 EPS).

Original reporting
Published Aug 9, 2026, 8:15 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 9, 2026, 8:16 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Interface, Inc. Q2 2026 Earnings Call Summary — source image
Decision brief

The 30-second read

$TILEBullishMed
01

Why it matters

The key tradable items are the raised FY 2026 guidance, the guided 2H gross margin run rate of about 39% (up 60 bps), and explicit assumptions around raw material inflation flow-through, pricing actions, tariffs, and FX translation.

02

Market read

Traders can update expectations for FY 2026 margins and earnings power based on the raised guidance and quantified 2H gross margin run-rate, while monitoring tariff and cost-of-sales sensitivity.

03

What to watch

Adjusted SG&A rose due to higher sales commissions and variable compensation, which could pressure operating leverage if revenue growth slows or pricing offsets inflation less effectively.

Relevance 7/10Novelty 7/10Timing: pre-market today, Q2 call summary with raised FY 2026 guidance and 2H gross margin run-rate

Background

The piece summarizes Interface, Inc.'s Q2 2026 earnings call, focusing on currency-neutral sales growth, margin drivers, and a raised full-year outlook.

Company-level read

Ticker impact

$TILEBullishMedium confidence
Context

Interface raised full-year 2026 guidance and guided to a ~39% second-half gross margin run rate, citing backlog growth and margin efficiency gains.

Expected impact

Moderately positive bias for the next few sessions as traders reprice FY margin and backlog momentum.

Evidence & confidence

The article provides specific, time-relevant guidance changes (raised FY guidance, 2H gross margin run rate, tariff and FX assumptions) that can directly affect valuation and positioning.

Market effects

Signals resilience in commercial flooring demand (Healthcare billings growth, return-to-office framing) and continued pricing discipline despite raw material inflation and tariffs.

Europe and Australia automation/robotics are cited as margin drivers, implying execution benefits in those regions.

Backlog and order momentum are described as broad-based across geographies, supporting a more constructive global demand read-through.

Counterpoint

Tariff exposure remains embedded in COGS (15% to 20% subject to ongoing tariffs), so margin upside may be less durable if tariff refunds do not recur.

Key entities

  • Interface, Inc.

    Reported Q2 performance, raised full-year 2026 guidance, and guided to a ~39% second-half gross margin run rate.

Related articles

$TILEMedAI 8/10

Why Is Interface (TILE) Stock Rocketing Higher Today

Interface (NASDAQ: TILE) shares rose after Q2 results beat expectations. Adjusted EPS was $0.88, about 38% above estimates, with adjusted operating margin up to 18.9% from 13.9%. Revenue was $395.7M (+5.4% YoY). Q3 sales guidance of $370M-$380M was slightly below consensus, while full-year sales was raised to $1.455B-$1.485B. Stock closed at $38.37, up 9.3%.

$TILEMedAI 8/10

Interface: Q2 Earnings Snapshot

Interface Inc. (TILE) reported Q2 net income of $51.4 million, or 88 cents per share, on revenue of $395.7 million. For the quarter ending September, the company forecast revenue of $370 million to $380 million. Full-year revenue guidance is $1.46 billion to $1.49 billion.

$TILEHigh

INTERFACE INC (TILE): Results of Operations and Financial Condition

INTERFACE INC (TILE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a991pressreleaseq22026.htm EX-99.1 Document FOR IMMEDIATE RELEASE Media Contact: Christine Needles Global Corporate Communications Christine.Needles@interface.com +1 404-491-4660 Investor Contact: Bruce Hausmann Chief Financial Officer Bruce.Hausmann@interface.com +1 77

$DVNMed

Devon Energy Q2 Earnings Call Highlights

Devon Energy (DVN) reported Q2 updates on reinvestment rate, production guidance, capital spending, and shareholder returns. It raised 2026 oil-production guidance to 495,000 to 505,000 bpd, forecast Q3 oil 550,000 to 560,000 bpd, and capex $4.8B to $5B for 2026. Devon said it returned over $1B in Q2 and completed $1.25B 2026 debt reduction.

$EBSHighAI 9/10

Emergent Biosolutions Q2 Earnings Call Highlights

Emergent BioSolutions (EBS) reported Q2 updates on its MCM and naloxone franchises. Management said MCM international sales were about 20% of first-half 2026 revenue. It received regulators’ approvals to expand ACAM2000 to Mpox. Due to NARCAN competition, EBS lowered 2026 revenue guidance to $645M-$675M and recorded a ~$191M non-cash impairment, plus ~$40M annualized cost savings.